Remepy has raised $36 million in Series A funding to advance its Hybrid Drug platform and prepare its lead Parkinson’s disease program, Hybridopa, for global Phase III clinical development. The company announced the financing on August 12, 2026, saying the round will also support pharmaceutical co-development partnerships and the expansion of its Hybrid Drug pipeline.
The latest financing brings Remepy’s total capital raised to $62 million. O.G. Venture Partners and M Ventures, the corporate strategic venture arm of Merck KGaA, Darmstadt, Germany, led the round. Existing and new investors also participated, including NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital and IT-Farm Corp.
Funding to Support Hybridopa’s Phase III Development
A major focus of the new funding will be Hybridopa, Remepy’s investigational Hybrid Drug program for Parkinson’s disease. Remepy plans to use the financing to fund global Phase III clinical development of Hybridopa, which the company expects to begin in the fourth quarter of 2026. The planned study represents an important next stage for the company as it moves its Parkinson’s program from earlier clinical testing toward a larger global trial.
Hybridopa combines prescription medicine with a personalized digital therapeutic approach. The program pairs carbidopa/levodopa with Remepy’s DopApp, a mobile application designed to provide adaptive motor, cognitive, and behavioral treatment protocols. Remepy calls this approach a “Hybrid Drug,” combining pharmaceutical treatment with personalized, AI-driven therapeutic applications. The company believes this model can bring different types of treatment together under a single therapeutic program.
Encouraging Phase IIa Results
Remepy’s decision to move Hybridopa toward Phase III follows results from a Phase IIa clinical study. The company previously reported that the study showed improvements in both motor and non-motor symptoms among people with Parkinson’s disease. The study also generated biological findings that supported the company’s research into how the digital component may contribute to the treatment effect.
Independent reporting on the Phase IIa trial said the randomized, double-blind, placebo-controlled study included 41 patients and lasted three weeks. Participants continued their existing levodopa treatment while receiving either the DopApp intervention or a placebo digital application. The reported results showed a greater improvement in the treatment group on the MDS-UPDRS measure compared with the placebo group.
However, Hybridopa remains an investigational treatment and is not approved by the U.S. Food and Drug Administration (FDA). The planned Phase III program will therefore be an important step in determining whether the treatment can demonstrate its effectiveness and support future regulatory applications.
Remepy Expands Pharmaceutical Partnerships
The Series A financing also comes as Remepy expands its work with pharmaceutical companies. Remepy recently announced a strategic collaboration with Merck KGaA to develop Hybrid Drugs across multiple indications. The collaboration will initially focus on rare tumors, according to the company. M Ventures’ participation in the Series A round adds to the relationship between the two companies.
The partnership reflects Remepy’s broader strategy of working with pharmaceutical companies to develop treatments that combine established medicines with personalized digital interventions. The company says its Hybrid Drug platform could also provide pharmaceutical companies with opportunities for lifecycle management, new intellectual property and differentiation of existing or future medicines. These are company claims and will need to be validated through further development and clinical work.
Building a New Drug-and-Software Model
Remepy is positioning its technology around the idea that prescription medicines can work alongside personalized digital interventions rather than being used as separate treatments.
Its approach aims to combine pharmacology with physical, cognitive and behavioral interventions delivered through digital technology. The company believes this could allow treatment programs to adapt to individual patient needs while maintaining the structure of a prescription-based therapy.
The model is particularly relevant to Parkinson’s disease, where patients can experience a wide range of motor and non-motor symptoms. Remepy is using Hybridopa to test whether combining standard pharmaceutical treatment with a structured digital intervention can improve outcomes beyond medication alone.
What Comes Next
The immediate priority for Remepy is preparing Hybridopa for global Phase III development, expected to begin in Q4 2026. At the same time, the company plans to expand its Hybrid Drug pipeline and deepen pharmaceutical co-development partnerships. The $36 million Series A gives Remepy significant new funding to pursue those goals. With $62 million raised in total, the company is now entering a critical stage of development.
For Hybridopa, the upcoming Phase III program will provide a larger test of the drug-and-digital approach. Its results will help determine whether Remepy can move its Hybrid Drug concept closer to a potential treatment for Parkinson’s disease and establish a broader platform for combining pharmaceutical medicines with personalized digital care.
